198 related articles for article (PubMed ID: 33051476)
1. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
Azuma S; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Kondo M; Numata K; Iwabuchi S; Kako M; Maeda S; Koizumi W; Atsuda K
Sci Rep; 2020 Oct; 10(1):17054. PubMed ID: 33051476
[TBL] [Abstract][Full Text] [Related]
2. Association of
Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi FG; Tamburini E; Vivaldi C; Rizzato MD; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino GG; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu S; Scartozzi M
Clin Cancer Res; 2020 Sep; 26(17):4485-4493. PubMed ID: 32371540
[TBL] [Abstract][Full Text] [Related]
3. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Yamauchi M; Ono A; Ishikawa A; Kodama K; Uchikawa S; Hatooka H; Zhang P; Teraoka Y; Morio K; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Hayes CN; Fujita M; Nakagawa H; Yasui W; Aikata H; Chayama K
Clin Transl Gastroenterol; 2020 May; 11(5):e00179. PubMed ID: 32677805
[TBL] [Abstract][Full Text] [Related]
4.
Marisi G; Petracci E; Raimondi F; Faloppi L; Foschi FG; Lauletta G; Iavarone M; Canale M; Valgiusti M; Neri LM; Ulivi P; Orsi G; Rovesti G; Vukotic R; Conti F; Cucchetti A; Ercolani G; Andrikou K; Cascinu S; Scartozzi M; Casadei-Gardini A
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330833
[TBL] [Abstract][Full Text] [Related]
5. NOS3 Gene rs1799983 and rs2070744 Polymorphisms in Patients with Unstable Angina.
Pawlik A; Błaszczyk H; Rać M; Maciejewska-Skrendo A; Safranow K; Dziedziejko V
J Vasc Res; 2020; 57(3):136-142. PubMed ID: 32224624
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
7. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
[TBL] [Abstract][Full Text] [Related]
8. Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine.
García-Martín E; Navarro-Muñoz S; Rodriguez C; Serrador M; Alonso-Navarro H; Calleja M; Turpín-Fenoll L; Recio-Bermejo M; García-Ruiz R; Millán-Pascual J; Navacerrada F; Plaza-Nieto JF; García-Albea E; Agúndez JAG; Jiménez-Jiménez FJ
Pharmacogenomics J; 2020 Jun; 20(3):426-432. PubMed ID: 31792366
[TBL] [Abstract][Full Text] [Related]
9. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.
Yang Y; Zhou Y; Lu M; An Y; Li R; Chen Y; Lu DR; Jin L; Zhou WP; Qian J; Wang HY
Mol Carcinog; 2012 Jul; 51(7):515-21. PubMed ID: 21656577
[TBL] [Abstract][Full Text] [Related]
10. Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study.
Gamil S; Erdmann J; Abdalrahman IB; Mohamed AO
BMC Med Genet; 2017 Nov; 18(1):128. PubMed ID: 29132319
[TBL] [Abstract][Full Text] [Related]
11. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes.
Ryk C; Koskela LR; Thiel T; Wiklund NP; Steineck G; Schumacher MC; de Verdier PJ
Redox Biol; 2015 Dec; 6():272-277. PubMed ID: 26298202
[TBL] [Abstract][Full Text] [Related]
12. Endothelial nitric oxide synthase (NOS3) rs2070744 polymorphism and risk for multiple sclerosis.
Agúndez JAG; García-Martín E; Rodríguez C; Benito-León J; Millán-Pascual J; Díaz-Sánchez M; Calleja P; Turpín-Fenoll L; Alonso-Navarro H; García-Albea E; Plaza-Nieto JF; Jiménez-Jiménez FJ
J Neural Transm (Vienna); 2020 Aug; 127(8):1167-1175. PubMed ID: 32449012
[TBL] [Abstract][Full Text] [Related]
13. PREDICTING THE OCCURRENCE OF PRIMARY OPEN-ANGLE GLAUCOMA DEPENDING ON THE GENETIC POLYMORPHISM ENDOTHELIAL NO SYNTHASE (NOS3) GENE.
Isaiev O; Serdiuk V; Ziablitsev D
Wiad Lek; 2022; 75(12):3087-3093. PubMed ID: 36723332
[TBL] [Abstract][Full Text] [Related]
14. Circadian Rhythms of Endothelial Nitric Oxide Synthase and Toll-like Receptors 2 Production in Females with Rheumatoid Arthritis Depending on NOS3 Gene Polymorphism.
Zaichko K; Zaichko N; Maievskyi O; Korotkyi O; Falalyeyeva T; Fagoonee S; Pellicano R; Abenavoli L; Stanislavchuk M
Rev Recent Clin Trials; 2020; 15(2):145-151. PubMed ID: 32297585
[TBL] [Abstract][Full Text] [Related]
15. The Association between NOS3 Gene Polymorphisms and Hypoxic-Ischemic Encephalopathy Susceptibility and Symptoms in Chinese Han Population.
Wu Y; Zhu Z; Fang X; Yin L; Liu Y; Xu S; Li A
Biomed Res Int; 2016; 2016():1957374. PubMed ID: 28070505
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.
Sheu MJ; Hsieh MJ; Chiang WL; Yang SF; Lee HL; Lee LM; Yeh CB
PLoS One; 2015; 10(4):e0122961. PubMed ID: 25860955
[TBL] [Abstract][Full Text] [Related]
17. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Yamaoka K; Kodama K; Kawaoka T; Kosaka M; Johira Y; Shirane Y; Miura R; Yano S; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Uchikawa S; Uchida T; Fujino H; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Miki D; Imamura M; Takahashi S; Nagao A; Chayama K; Aikata H
PLoS One; 2022; 17(1):e0262675. PubMed ID: 35041693
[TBL] [Abstract][Full Text] [Related]
18. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
19. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
[TBL] [Abstract][Full Text] [Related]
20. Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature.
Shibata O; Kamimura K; Ko M; Sakai N; Abe H; Morita S; Mizusawa T; Sato H; Sakamaki A; Terai S
Intern Med; 2021 Jun; 60(11):1709-1715. PubMed ID: 33390501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
